Who are Pramlintide and glucagon's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pramlintide-and-glucagon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Pramlintide and glucagon — Competitive Intelligence Brief

Pramlintide and glucagon (Pramlintide and glucagon) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amylin analog with glucagon co-formulation. Area: Diabetes.

phase 3 Amylin analog with glucagon co-formulation Amylin receptor (pramlintide); glucagon receptor (glucagon) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Pramlintide and glucagon (Pramlintide and glucagon) — Baylor College of Medicine. This combination uses pramlintide to slow gastric emptying and suppress glucagon secretion, while glucagon provides a rapid-acting counter-regulatory hormone to prevent hypoglycemia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pramlintide and glucagon TARGET	Pramlintide and glucagon	Baylor College of Medicine	phase 3	Amylin analog with glucagon co-formulation	Amylin receptor (pramlintide); glucagon receptor (glucagon)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amylin analog with glucagon co-formulation class)

Baylor College of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pramlintide and glucagon — Competitive Intelligence Brief. https://druglandscape.com/ci/pramlintide-and-glucagon. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab